Compare Wahed FTSE USA Shariah ETF (HLAL) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Wahed FTSE USA Shariah ETF vs Medpace Holdings Inc — how do they compare? Wahed FTSE USA Shariah ETF trades at $71.28, while Medpace Holdings Inc trades at $528.16 (market cap $15.18B). The key difference: Wahed FTSE USA Shariah ETF is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals.
| HLAL | MEDP | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $73.60 | $620.59 |
52-Week Low | $54.05 | $393.42 |
Market Cap | — | $15.18B |
Enterprise Value | — | $14.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HLAL trades at $70.22, down 0.17% on the day, with a bearish technical signal from moving averages and neutral oscillators. The stock faces resistance at $71 and support at $70. Key financial ratios including P/E, P/S, and ROE are unavailable in the current dataset, limiting fundamental assessment. A small dividend of $0.02 is scheduled for June 2026.
The outlook remains cautious due to weak technical momentum and incomplete fundamental data. Investment opportunity hinges on upcoming financial disclosures to validate valuation. Primary risks include market volatility and lack of recent business updates. Analyst sentiment appears neutral to bearish given the technical configuration.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Wahed FTSE USA Shariah ETF
HLAL is an ETF that invests in Shariah-compliant US companies. It follows a rigorous screening process to exclude businesses involved in non-compliant activities like interest-based finance, alcohol, and gambling.
Read more on HLAL →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
